English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Inhaled dry powders are the preferred route of delivery for many respiratory medicines. Toxicology studies are routinely carried out on inhaled dry powders whereas early pre-clinical in vivo efficacy studies often use aqueous formulations. Ideally evaluation of in- vivo efficacy, duration of action and DMPK of novel compounds, delivered as dry powders, should be carried out at an earlier stage in the drug development process. This would allow direct comparisons to be made with toxicology data to establish a therapeutic index and enable a more relevant prediction of clinical efficacy.

Dry powder inhaled compound delivery for early pre-clinical in vivo efficacy studies